These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 31942947)

  • 1. Drug-drug Interactions Among Thai Transgender Women Living with Human Immunodeficiency Undergoing Feminizing Hormone Therapy and Antiretroviral Therapy: The iFACT Study.
    Hiransuthikul A; Himmad L; Kerr SJ; Janamnuaysook R; Dalodom T; Phanjaroen K; Pankam T; Kongkapan J; Mills S; Vannakit R; Phanuphak P; Phanuphak N
    Clin Infect Dis; 2021 Feb; 72(3):396-402. PubMed ID: 31942947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-drug interactions between feminizing hormone therapy and pre-exposure prophylaxis among transgender women: the iFACT study.
    Hiransuthikul A; Janamnuaysook R; Himmad K; Kerr SJ; Thammajaruk N; Pankam T; Phanjaroen K; Mills S; Vannakit R; Phanuphak P; Phanuphak N;
    J Int AIDS Soc; 2019 Jul; 22(7):e25338. PubMed ID: 31298497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of feminizing hormone therapy on tenofovir and emtricitabine plasma pharmacokinetics: a nested drug-drug interaction study in a cohort of Brazilian transgender women using HIV pre-exposure prophylaxis.
    Cattani VB; Jalil EM; Eksterman L; Torres T; Cardoso SW; Castro CRV; Monteiro L; Wilson E; Bushman L; Anderson P; Veloso VG; Grinsztejn B; Estrela R;
    J Antimicrob Chemother; 2022 Sep; 77(10):2729-2736. PubMed ID: 35815666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estradiol and Spironolactone Plasma Pharmacokinetics Among Brazilian Transgender Women Using HIV Pre-Exposure Prophylaxis: Analysis of Potential Interactions.
    Cattani VB; Jalil EM; Eksterman L; Torres T; Wagner Cardoso S; Castro CRV; Monteiro L; Wilson E; Bushman L; Anderson P; Veloso VG; Grinsztejn B; Estrela R;
    Clin Pharmacokinet; 2023 Jul; 62(7):1031-1041. PubMed ID: 37261664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sex Hormone Therapy and Tenofovir Diphosphate Concentration in Dried Blood Spots: Primary Results of the Interactions Between Antiretrovirals And Transgender Hormones Study.
    Grant RM; Pellegrini M; Defechereux PA; Anderson PL; Yu M; Glidden DV; O'Neal J; Yager J; Bhasin S; Sevelius J; Deutsch MB
    Clin Infect Dis; 2021 Oct; 73(7):e2117-e2123. PubMed ID: 32766890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feminizing hormone therapy in a Canadian cohort of transgender women with and without HIV.
    Armstrong I; Lacombe-Duncan A; Shokoohi M; Persad Y; Tseng A; Fung R; Underhill A; Côté P; Machouf N; Saucier A; Varriano B; Brundage M; Jones R; Weisdorf T; Goodhew J; MacLeod J; Loutfy M
    Antivir Ther; 2023 Jun; 28(3):13596535231182505. PubMed ID: 37289725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bidirectional pharmacokinetics of doravirine, tenofovir, and feminizing hormones in transgender women (IDentify): A randomized crossover trial.
    Lam K; Kraft WK; Zhan T; Lam E
    Clin Transl Sci; 2024 Mar; 17(3):e13721. PubMed ID: 38421210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients.
    Dejesus E; Young B; Morales-Ramirez JO; Sloan L; Ward DJ; Flaherty JF; Ebrahimi R; Maa JF; Reilly K; Ecker J; McColl D; Seekins D; Farajallah A;
    J Acquir Immune Defic Syndr; 2009 Jun; 51(2):163-74. PubMed ID: 19357529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transgender women, hormonal therapy and HIV treatment: a comprehensive review of the literature and recommendations for best practices.
    Radix A; Sevelius J; Deutsch MB
    J Int AIDS Soc; 2016; 19(3 Suppl 2):20810. PubMed ID: 27431475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gender affirmative HIV care framework: Decisions on feminizing hormone therapy (FHT) and antiretroviral therapy (ART) among transgender women.
    Restar AJ; Santamaria EK; Adia A; Nazareno J; Chan R; Lurie M; Sandfort T; Hernandez L; Cu-Uvin S; Operario D
    PLoS One; 2019; 14(10):e0224133. PubMed ID: 31634378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of Co-Formulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate After Switch From Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Healthy Subjects.
    Ramanathan S; Custodio JM; Wei X; Wang H; Fordyce M; Dave A; Ling KH; Szwarcberg J; Kearney BP
    J Acquir Immune Defic Syndr; 2016 Jul; 72(3):281-8. PubMed ID: 26885802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment.
    Wilkins EL; Cohen CJ; Trottier B; Esser S; Smith DE; Haas B; Brinson C; Garner W; Chuck S; Thorpe D; De-Oertel S
    AIDS Care; 2016; 28(3):401-8. PubMed ID: 26489045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Comparison of Plasma Efavirenz and Tenofovir, Dried Blood Spot Tenofovir-Diphosphate, and Self-Reported Adherence to Predict Virologic Suppression Among South African Women.
    Phillips TK; Sinxadi P; Abrams EJ; Zerbe A; Orrell C; Hu NC; Brittain K; Gomba Y; Norman J; Wiesner L; Myer L; Maartens G
    J Acquir Immune Defic Syndr; 2019 Jul; 81(3):311-318. PubMed ID: 30893125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors associated with daily tenofovir exposure in Thai subjects taking combination antiretroviral therapy.
    Kerr SJ; Punyawudho B; Thammajaruk N; Colbers A; Chaiyahong P; Phonphithak S; Sapsirisavat V; Ruxrungtham K; Burger DM; Avihingsanon A
    AIDS Res Hum Retroviruses; 2015 Apr; 31(4):368-74. PubMed ID: 25384393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics of tenofovir, emtricitabine and intracellular metabolites in transgender women.
    Tanaudommongkon A; Chaturvedula A; Hendrix CW; Fuchs EJ; Shieh E; Bakshi RP; Marzinke MA
    Br J Clin Pharmacol; 2022 Aug; 88(8):3674-3682. PubMed ID: 35285974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Point-of-Care Tenofovir Urine Testing for the Prediction of Treatment Failure and Drug Resistance During Initial Treatment for Human Immunodeficiency Virus Type 1 (HIV-1) Infection.
    Hermans LE; Umunnakwe CN; Lalla-Edward ST; Hebel SK; Tempelman HA; Nijhuis M; Venter WDF; Wensing AMJ
    Clin Infect Dis; 2023 Feb; 76(3):e553-e560. PubMed ID: 36136811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methotrexate Decreases Tenofovir Exposure in Antiretroviral-Suppressed Individuals Living With HIV.
    Gingrich D; Deitchman AN; Kantor A; Huang L; Stein JH; Currier JS; Hsue PY; Ribaudo HJ; Aweeka FT;
    J Acquir Immune Defic Syndr; 2020 Dec; 85(5):651-658. PubMed ID: 33177476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance of HIV pre-exposure prophylaxis indirect adherence measures among men who have sex with men and transgender women: Results from the PrEP Brasil Study.
    Marins LMS; Torres TS; Leite IDC; Moreira RI; Luz PM; Hoagland B; Kallas EG; Madruga JV; Liu AY; Anderson PL; Grinsztejn B; Veloso VG
    PLoS One; 2019; 14(8):e0221281. PubMed ID: 31430318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protocol of a drug-drug interaction study between bictegravir/emtricitabine/tenofovir alafenamide and feminizing hormones in trans women living with HIV.
    Lacombe-Duncan A; Tseng A; Scarsi KK; Senneker T; Kluger H; Persad Y; Underhill A; Kennedy VL; Armstrong I; Fung R; Bourns A; Nguyen Q; Hranilovic S; Weisdorf T; Chan L; Kia H; Halpenny R; Iyer H; Jeyarajah N; Kovchazov G; Tharao W; Loutfy M
    Br J Clin Pharmacol; 2024 Jul; ():. PubMed ID: 38992893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Highly Active Antiretroviral Therapy on Albuminuria in HIVinfected Persons.
    Adedeji TA; Adebisi SA; Adedeji NO
    Infect Disord Drug Targets; 2020; 20(3):374-384. PubMed ID: 31389318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.